MINNEAPOLIS, July 28 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products, announced today that it will participate in two upcoming investor conferences.
The Company will participate in the 9th Annual BMO Capital Markets Focus on Healthcare Conference at the Millennium Broadway Hotel in New York. Michael Kramer, CFO of ATS Medical, will present at 4:30 p.m. Eastern Time on Wednesday, August 5, 2009. Attendance at the conference is by invitation only.
The Company will also participate in the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental Hotel in Boston, MA. Michael Dale, President and CEO of ATS Medical, will present at 8:30 a.m. Eastern Time on Thursday, August 13th, 2009. Attendance at the conference is by invitation only.
A live audio-only webcast of each presentation will be broadcast via the Internet. Those interested in listening to the webcasts may access them at ATS Medical's website at www.atsmedical.com.
About ATS Medical
ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.
ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.
|SOURCE ATS Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved